Erratum: Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial (The Lancet (2017) 389(10064) (67–76)(S0140673616324552)(10.1016/S0140-6736(16)32455-2));Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial

The Lancet

Volumn 389, Issue 10064, 2017, Pages 67-76

  Balar, Arjun V ^a   Galsky, Matthew D ^b   Rosenberg, Jonathan E ^c   Powles, Thomas ^d   Petrylak, Daniel P ^e   Bellmunt, Joaquim ^f   Loriot, Yohann ^g   Necchi, Andrea ^h   Hoffman Censits, Jean ⁱ   Perez Gracia, Jose Luis ^j   Dawson, Nancy A ^k   van der Heijden, Michiel S ^l   Dreicer, Robert ^m   Srinivas, Sandy ⁿ   Retz, Margitta M ^o   Joseph, Richard W ^p   Drakaki, Alexandra ^q   Vaishampayan, Ulka N ^r   Sridhar, Srikala S ^s   Quinn, David I ^t   Durán, Ignacio ^u   Shaffer, David R ^v   Eigl, Bernhard J ^w   Grivas, Petros D ^x   Yu, Evan Y ^y   Li, Shi ^z   Kadel, Edward E ^z   Boyd, Zachary ^z   Bourgon, Richard ^z   Hegde, Priti S ^z   Mariathasan, Sanjeev ^z   Thåström, AnnChristine ^z   Abidoye, Oyewale O ^z   Fine, Gregg D ^z   Bajorin, Dean F ^c   more..

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^e YALE UNIVERSITY   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

^g UNIVERSITÉ PARIS SACLAY   (France)

^h NATIONAL CANCER INSTITUTE   (Italy)

ⁱ THOMAS JEFFERSON UNIVERSITY   (United States)

^j UNIVERSITY CLINIC OF NAVARRA   (Spain)

^k GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^l NETHERLANDS CANCER INSTITUTE   (Netherlands)

^m UNIVERSITY OF VIRGINIA   (United States)

ⁿ STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^o TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^p MAYO CLINIC   (United States)

^q UNIVERSITY OF CALIFORNIA   (United States)

^r WAYNE STATE UNIVERSITY   (United States)

^s PRINCESS MARGARET HOSPITAL   (Canada)

^t UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^u Instituto de Biomedicina de Sevilla   (Spain)

^v New York Oncology Hematology   (United States)

^w BRITISH COLUMBIA CANCER AGENCY   (Canada)

^x TAUSSIG CANCER INSTITUTE   (United States)

^y UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^z GENENTECH INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ATEZOLIZUMAB; BILIRUBIN; CARBOPLATIN; CISPLATIN; CORTICOSTEROID; GEMCITABINE; ANTINEOPLASTIC AGENT; CD274 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 LIGAND 1; TUMOR MARKER;

ACNE; ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; AUTOIMMUNE DISEASE; BACKACHE; BILIRUBIN BLOOD LEVEL; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CHILL; COLITIS; CORTICOSTEROID THERAPY; DECREASED APPETITE; DERMATITIS; DIARRHEA; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; EUROPE; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; FOLLOW UP; HEADACHE; HUMAN; HYPERSENSITIVITY; HYPOPHOSPHATEMIA; HYPOTENSION; HYPOTHYROIDISM; IMMUNOPATHOLOGY; INFUSION RELATED REACTION; KIDNEY FAILURE; LIVER DISEASE; LYMPHOCYTE COUNT; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE ORGAN FAILURE; MUSCLE SPASM; MUTATIONAL LOAD; NAUSEA; NORTH AMERICA; PHASE 2 CLINICAL TRIAL; PORTAL VEIN THROMBOSIS; PRIMARY TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RASH; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; SEPSIS; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; TREATMENT DURATION; TREATMENT RESPONSE; VERY ELDERLY; VOMITING; XEROSTOMIA; BLOOD; CARCINOMA, TRANSITIONAL CELL; CLINICAL TRIAL; CONTRAINDICATIONS; INTRAVENOUS DRUG ADMINISTRATION; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MIDDLE AGED; SECONDARY; UROLOGIC NEOPLASMS;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIGENS, CD274; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; CARCINOMA, TRANSITIONAL CELL; CISPLATIN; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; UROLOGIC NEOPLASMS;

EID: 85007564166     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(17)32213-4     Document Type: Erratum

References (30)

1. 1 National Cancer Institute Surveillance, Spidemiology and End Results Program. SEER cancer statistics factsheets: Bladder cancer. http://seer.cancer.gov/statfacts/html/urinb.html (accessed Aug 12, 2016).
2. 2 Ferlay, J, Soerjomataram, I, Ervik, M, et al. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase no. 11. http://globocan.iarc.fr/Pages/summary_table_site_sel.aspx (accessed Sept 13, 2016).
3. 3 Loehrer, PJ Sr, Einhorn, LH, Elson, PJ, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 10 (1992), 1066–1073.
4. 4 Galsky, MD, Hahn, NM, Rosenberg, J, et al. Treatment of patients with metastatic urothelial cancer “unfit” for cisplatin-based chemotherapy. J Clin Oncol 29 (2011), 2432–2438.
5. 5 Bellmunt, J, Orsola, A, Leow, JJ, et al. Bladder cancer: ESMO practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 25:suppl 3 (2014), iii40–iii48.
6. 6 National Comprehensive Cancer Network. Clinical practice guidelines in oncology: bladder cancer. Version 2. https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf, 2016 (accessed Aug 24, 2016).
7. 7 De Santis, M, Wiechno, PJ, Bellmunt, J, et al. Vinflunine-gemcitabine versus vinflunine-carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1). Ann Oncol 27 (2016), 449–454.
8. 8 Necchi, A, Pond, GR, Raggi, D, et al. Efficacy and safety of gemcitabine plus either taxane or carboplatin in the first-line setting of metastatic urothelial carcinoma: a systematic review and meta-analysis. Clin Genitourin Cancer, 2016, 10.1016/j.clgc.2016.05.003 published online May 27.
9. 9 De Santis, M, Bellmunt, J, Mead, G, et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol 30 (2012), 191–199.
10. 10 Galsky, MD, Pal, SK, Lin, SW, et al. 2624 the effectiveness of chemotherapy in “real world” patients with metastatic bladder cancer. Eur J Cancer 51:suppl 3 (2015), S520–S521.
11. 11 Sonpavde, G, Galsky, MD, Latini, D, Chen, GJ, Cisplatin-ineligible and chemotherapy-ineligible patients should be the focus of new drug development in patients with advanced bladder cancer. Clin Genitourin Cancer 12 (2014), 71–73.
12. 12 Herbst, RS, Soria, JC, Kowanetz, M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515 (2014), 563–567.
13. 13 Powles, T, Eder, JP, Fine, GD, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515 (2014), 558–562.
14. 14 Fehrenbacher, L, Spira, A, Ballinger, M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 387 (2016), 1837–1846.
15. 15 McDermott, DF, Sosman, JA, Sznol, M, et al. Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase Ia study. J Clin Oncol 34 (2016), 833–842.
16. 16 Rosenberg, JE, Hoffman-Censits, J, Powles, T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387 (2016), 1909–1920.
17. 17 Galsky, MD, Hahn, NM, Rosenberg, J, et al. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol 12 (2011), 211–214.
18. 18 Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507 (2014), 315–322.
19. 19 Bajorin, DF, Dodd, PM, Mazumdar, M, et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 17 (1999), 3173–3181.
20. 20 von der Maase, H, Sengelov, L, Roberts, JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23 (2005), 4602–4608.
21. 21 Bellmunt, J, von der Maase, H, Mead, GM, et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC intergroup study 30987. J Clin Oncol 30 (2012), 1107–1113.
22. 22 Motzer, RJ, Escudier, B, McDermott, DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373 (2015), 1803–1813.
23. 23 Damrauer, JS, Hoadley, KA, Chism, DD, et al. Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc Natl Acad Sci USA 111 (2014), 3110–3115.
24. 24 Choi, W, Porten, S, Kim, S, et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 25 (2014), 152–165.
25. 25 Lawrence, MS, Stojanov, P, Polak, P, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499 (2013), 214–218.
26. 26 Rizvi, NA, Hellmann, MD, Snyder, A, et al. Cancer immunology. mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348 (2015), 124–128.
27. 27 Van Allen, EM, Miao, D, Schilling, B, et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350 (2015), 207–211.
28. 28 Hutchinson, R, Haddad, A, Sagalowsky, A, Margulis, V, Upper tract urothelial carcinoma: special considerations. Clin Adv Hematol Oncol 14 (2016), 101–109.
29. 29 Le, DT, Uram, JN, Wang, H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372 (2015), 2509–2520.
30. 30 Taylor, JAI, Kuchel, GA, Bladder cancer in the elderly: clinical outcomes, basic mechanisms, and future research direction. Nat Clin Pract Urol 6 (2009), 135–144.